GSK plc will present 21 abstracts highlighting advances in its liver disease pipeline at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025, held in Washington D.C. from 7–11 November. The presentations will feature new data from two late-stage candidates, bepirovirsen and efimosfermin, alongside updates on linerixibat.
Key Highlights
- Type: Antisense oligonucleotide (ASO) therapy
- Study: B-Sure Phase II sub-analysis
- Focus: Evaluating achievement and durability of a functional cure in CHB patients treated with bepirovirsen followed by Peg-IFN therapy.
Efimosfermin: FGF21 Analog for MASH and ALD
- Type: Once-monthly fibroblast growth factor 21 (FGF21) analog
- Results: Phase II data show sustained improvements in fibrosis and MASH resolution at 48 weeks for patients with F2/F3 fibrosis.
- Next Steps: Data support the initiation of ZENITH-1 and ZENITH-2 Phase III trials for moderate and advanced fibrosis due to MASH.
- ALD Update: Early findings from the ‘990 STARLIGHT’ study indicate favorable safety trends and reduced liver enzyme levels, even with continued alcohol consumption.
Linerixibat: Managing Cholestatic Pruritus
- Focus: Data reinforce linerixibat’s mechanism of action and safety in cholestatic pruritus, supported by Phase III GLISTEN study results recently published in The Lancet Gastroenterology & Hepatology.
- Indication: Treatment for primary biliary cholangitis (PBC), an autoimmune liver condition that can lead to liver failure.
GSK’s Broader Liver Disease Strategy
GSK’s hepatology R&D is driven by deep expertise in fibrosis and inflammation, targeting chronic hepatitis B, primary biliary cholangitis, and advanced steatotic liver diseases such as MASH and alcohol-associated liver disease (ALD).
With one in 25 global deaths linked to liver disease, GSK aims to advance immune-driven therapies that can halt or reverse disease progression.
“Our growing liver disease pipeline reflects GSK’s commitment to applying immunology and advanced technologies to address fibro-inflammatory conditions that affect millions worldwide,” the company said in a statement.
About GSK
GSK is a global biopharmaceutical company uniting science, technology, and talent to get ahead of disease together.
